Cardiovascular disease and radiopharmaceutical therapies- an underestimated risk?
作者信息
Lassmann Michael, Eberlein Uta, Verburg Frederik A
机构信息
Department of Nuclear Medicine, University Hospital Würzburg, D-97080, Würzburg, Germany.
Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, 3015 GD, The Netherlands.
出版信息
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1246-1248. doi: 10.1007/s00259-024-07039-4.
Abstract
摘要
相似文献
1
Cardiovascular disease and radiopharmaceutical therapies- an underestimated risk?心血管疾病与放射性药物治疗——一种被低估的风险？
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1246-1248. doi: 10.1007/s00259-024-07039-4.
2
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.基于影像的剂量学在癌症放射性药物治疗个体化中的应用。
Cancer Imaging. 2022 Dec 9;22(1):67. doi: 10.1186/s40644-022-00505-y.
3
Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review.β粒子发射放射性药物治疗中肾组织内吸收剂量分布的异质性与肾毒性的剂量反应建模：综述。
Z Med Phys. 2024 Nov;34(4):491-509. doi: 10.1016/j.zemedi.2023.02.006. Epub 2023 Apr 6.
4
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.评估 PSMA 放射性药物治疗的反应：注射后 24 小时进行单光子发射计算机断层扫描成像。
J Nucl Med. 2024 Jul 1;65(7):1064-1069. doi: 10.2967/jnumed.123.267208.
5
Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis.锕-227对加速器生产的用于血液系统恶性肿瘤患者α发射体放射性药物治疗的锕-225的剂量学影响：药代动力学建模分析
EJNMMI Phys. 2021 Aug 18;8(1):60. doi: 10.1186/s40658-021-00410-6.
6
Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters.技术说明：在使用剂量体素核素估算涉及α发射体的放射性药物治疗吸收剂量时引入的误差。
Med Phys. 2024 Aug;51(8):5764-5772. doi: 10.1002/mp.16970. Epub 2024 Feb 5.
7
Active and passive dosimetry for beta-emitting radiopharmaceutical therapy agents in a custom SPECT/CT compatible phantom.用于定制 SPECT/CT 兼容体模中β发射放射性药物治疗剂的主动和被动剂量测定。
Phys Med Biol. 2024 May 23;69(11). doi: 10.1088/1361-6560/ad450c.
8
Effect of Au-197 nanoparticles along with Sm-153 radiopharmaceutical in prostate cancer from simulation method.
J Cancer Res Ther. 2019 Mar;15(Supplement):S42-S46. doi: 10.4103/jcrt.JCRT_183_17.
9
Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to Lu-PSMA therapy of prostate cancer.实体瘤中放射性药物转运的时空建模：在前列腺癌镥-PSMA治疗中的应用。
Comput Methods Programs Biomed. 2024 Mar;245:108004. doi: 10.1016/j.cmpb.2023.108004. Epub 2024 Jan 1.
10
A novel fast strategy to calculate equieffective doses under different dose rate conditions.一种在不同剂量率条件下计算等效剂量的新型快速策略。
Med Phys. 2025 May;52(5):3416-3427. doi: 10.1002/mp.17688. Epub 2025 Feb 15.
本文引用的文献
1
Consequences of ionizing radiation exposure to the cardiovascular system.电离辐射对心血管系统的影响。
Nat Rev Cardiol. 2024 Dec;21(12):880-898. doi: 10.1038/s41569-024-01056-4. Epub 2024 Jul 10.
2
Renal and Multiorgan Safety of Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.Lu-PSMA-617 在 VISION 剂量学亚研究中转移性去势抵抗性前列腺癌患者的肾和多器官安全性。
J Nucl Med. 2024 Jan 2;65(1):71-78. doi: 10.2967/jnumed.123.265448.
3
Ionising radiation and cardiovascular disease: systematic review and meta-analysis.电离辐射与心血管疾病：系统综述和荟萃分析。
BMJ. 2023 Mar 8;380:e072924. doi: 10.1136/bmj-2022-072924.
4
Radioactive Iodine Treatment and the Risk of Long-Term Cardiovascular Morbidity and Mortality in Thyroid Cancer Patients: A Nationwide Cohort Study.放射性碘治疗与甲状腺癌患者长期心血管疾病发病率及死亡率风险：一项全国性队列研究
J Clin Med. 2021 Sep 6;10(17):4032. doi: 10.3390/jcm10174032.
5
Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study.放射性碘治疗对甲状腺癌患者心血管疾病的影响：一项全国性队列研究。
Ann Transl Med. 2020 Oct;8(19):1235. doi: 10.21037/atm-20-5222.
6
DNA damage in blood leucocytes of prostate cancer patients during therapy with Lu-PSMA.前列腺癌患者在接受 Lu-PSMA 治疗期间血液白细胞中的 DNA 损伤。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1723-1732. doi: 10.1007/s00259-019-04317-4. Epub 2019 Apr 27.
7
DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.（177）Lu肽受体放射性核素治疗后患者血液淋巴细胞中的DNA损伤
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1739-1749. doi: 10.1007/s00259-015-3083-9. Epub 2015 Jun 6.
8
Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.分化型甲状腺癌患者的长期心血管死亡率：一项观察性研究。
J Clin Oncol. 2013 Nov 10;31(32):4046-53. doi: 10.1200/JCO.2013.49.1043. Epub 2013 Oct 7.
9
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.对于甲状腺癌患者，血液吸收剂量比所给予的 131I 活度更能预测消融治疗的成功。
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):673-80. doi: 10.1007/s00259-010-1689-5. Epub 2011 Jan 6.
Zotero 插件